NEJM Publishes Landmark Study on Promising Targeted Therapy for Pancreatic Cancer
At the ASCO Presidential Symposium, long-awaited data from the NAPOLI-3 trial were presented and published in NEJM. The NALIRIFOX regimen (liposomal irinotecan combined with 5-fluorouracil, leucovorin, and oxaliplatin) demonstrated unprecedented overall survival in metastatic pancreatic cancer, establishing a new standard of first-line therapy.
Analytical Review: NEJM Publishes NAPOLI-3 — A New Era in Pancreatic Cancer or a Statistical Trick?
Analysis Date: May 29, 2026
[The Gist]: What's Really Happening
On the surface — the long-awaited publication of the NAPOLI-3 trial in NEJM, with the NALIRIFOX regimen recognized as the new first-line standard for metastatic pancreatic cancer. Overall survival improved to 11.1 months versus 9.2 months with Gemcitabine/nab-paclitaxel.
But the devil, as always, is in the details.
The NAPOLI-3 trial (NCT04083235) included 770 previously untreated patients with metastatic pancreatic adenocarcinoma. Results presented at the ASCO Presidential Symposium: median overall survival 11.1 months versus 9.2 months in the control group (HR 0.83; 95% CI 0.70-0.99; p=0.036), progression-free survival 7.4 months versus 5.6 months (HR 0.69; 95% CI 0.58-0.83; p<0.0001), objective response rate 41.8% versus 36.2%.
The key non-obvious insight that doesn't make headlines:
The main secret of NALIRIFOX is not liposomal irinotecan as a molecule, but the lower dose of oxaliplatin. NALIRIFOX uses 60 mg/m² of oxaliplatin versus 85 mg/m² in classic FOLFIRINOX. This deliberate reduction in toxicity allows patients to stay on therapy longer. It is the duration of exposure, not the initial dose intensity, that turned out to be the key factor in survival. Patients who required oxaliplatin dose reduction lived a median of 13.5 months versus 7.7 months for those who received the full dose without reduction. Most of the 'long-term survivors' from NAPOLI-3 — patients surviving 18+ months — had dose reductions of both irinotecan and oxaliplatin.
Timeline and Context
February 2024 — FDA approves NALIRIFOX for first-line metastatic pancreatic cancer based on interim data from NAPOLI-3.
May 2026 — Full data publication in NEJM and presentation at ASCO.
Key figures from the publication:
- Overall survival: 11.1 vs 9.2 months (difference — 1.9 months)
- One-year survival: 45.1% vs 38.5%
- Two-year survival: 20.3% vs 15.9%
Note: The control group received Gemcitabine/nab-paclitaxel, which has been the standard for the last 10 years. There is no randomized comparison with FOLFIRINOX.
Who Wins and Who Loses
Winner — Ipsen. Onivyde (liposomal irinotecan) brought the company €164 million ($176 million) in 2025. First-line approval opens a market 2-3 times larger. Analysts forecast sales growth to $400-500 million by 2028.
Winners — Patients with unresectable tumors and excellent performance status. Yes, a 1.9-month survival difference is progress. In pancreatic cancer, every month counts.
Loser — Bristol-Myers Squibb. Their drug Abraxane (nab-paclitaxel) in combination with gemcitabine was the standard for 10 years. Now NCCN guidelines will shift toward NALIRIFOX as the preferred regimen.
*Non-obvious loser — Patients with UGT1A128 mutation.* NAPOLI-3 investigators claim that homozygosity for UGT1A128 is not associated with increased toxicity of liposomal irinotecan. This contradicts decades of clinical experience with conventional irinotecan, where this mutation requires a 30% dose reduction. Grade 3-4 diarrhea in the homozygous group was 61.5%. This is unacceptably high. Physicians will still reduce doses.
What the Media Isn't Saying
First. The 1.9-month difference in overall survival barely reached statistical significance: p=0.036 — just above the 0.05 threshold. The confidence interval (0.70-0.99) almost touches 1.0. If the trial had been slightly smaller, the result might have been non-significant.
Second. Comparison with FOLFIRINOX — the only real competitor — is absent. Retrospective data show that NALIRIFOX and FOLFIRINOX have comparable efficacy. However, toxicity profiles differ: NALIRIFOX has less neutropenia (due to the lower oxaliplatin dose) but more grade 3 diarrhea.
Third (and most important for practicing oncologists). The NAPOLI-3 analysis showed that dose reduction is not a compromise but a strategy. Patients with oxaliplatin dose reduction lived a median of 13.5 months versus 7.7 months for those receiving the full dose without reduction. Patients with irinotecan dose reduction: 12.6 months versus 9.4 months. The key survival factor is not initial intensity but the patient's ability to stay on treatment longer. This overturns the traditional oncology paradigm of 'maximum tolerated dose.'
Fourth. The response rate of 41.8% is impressive. But in real-world clinical practice, outside strict clinical trial selection criteria, this figure will be lower. A retrospective Flatiron Health analysis showed a median survival of 9 months on FOLFIRINOX in real-world practice, notably lower than randomized trial results.
Forecast: Next 30 Days and 90 Days
30 days:
National clinical guidelines will begin to be revised. NCCN (USA) and ESMO (Europe) will update their guidelines, adding NALIRIFOX as a preferred first-line option alongside FOLFIRINOX.
Ipsen will launch an educational campaign for oncologists, emphasizing not the 1.9-month advantage but the possibility of flexible dosing and toxicity management. Key message: 'We can treat patients longer because toxicity is manageable.'
90 days:
First real-world data on NALIRIFOX use in clinical practice outside the US (Europe, Asia) will emerge. Japan is of particular interest, where the frequency of the UGT1A1*28 mutation is higher than the population average.
EMA is expected to decide on expanding Onivyde's indication in Europe. Approval likelihood is high, but additional pharmacogenetic testing data may be required.
Long-term forecast (2026-2028):
NALIRIFOX and FOLFIRINOX will coexist as two equivalent first-line regimens. Choice will be determined by toxicity profile: NALIRIFOX is preferred for patients with baseline neuropathy or risk of neutropenia, FOLFIRINOX for patients with good bone marrow reserve and no risk of severe diarrhea.
The main change brought by NAPOLI-3 is not in the survival numbers themselves, but in the paradigm shift in dosing. Oncologists will stop pursuing the maximum dose at all costs. And this may be a more valuable lesson than the added 1.9 months.
And finally: don't expect a miracle. Median survival in metastatic pancreatic cancer is still measured in months, not years. 11.1 months is progress. But it's not a breakthrough. The real breakthrough will come when targeted therapy or immunotherapy is added to this regimen. For now, we've simply learned to use what we already have a little better.
— Editorial Team
